Hydroxyurea
- Generic Name
- Hydroxyurea
- Brand Names
- Droxia, Hydrea, Siklos, Xromi
- Drug Type
- Small Molecule
- Chemical Formula
- CH4N2O2
- CAS Number
- 127-07-1
- Unique Ingredient Identifier
- X6Q56QN5QC
- Background
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
- Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
- Associated Therapies
- Chemoradiotherapy, Radiation Therapy
Treatment of Hemoglobin SC Disease With Hydroxyurea
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 32
- Registration Number
- NCT02336373
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Therapeutic Response Evaluation and Adherence Trial (TREAT)
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 150
- Registration Number
- NCT02286154
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 62
- Registration Number
- NCT02258659
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2019-08-06
- Target Recruit Count
- 10
- Registration Number
- NCT02225132
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML
- First Posted Date
- 2014-08-12
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 170
- Registration Number
- NCT02214407
- Locations
- 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷CHU La Réunion - Site nord, Saint-Denis, La Réunion, France
🇫🇷Chu Amiens, Amiens, France
Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment
- First Posted Date
- 2014-05-29
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 53
- Registration Number
- NCT02149537
- Locations
- 🇳🇬
University of Ibadan College of Medicine, Ibadan, Oyo State, Nigeria
Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Children's National Research Institute
- Registration Number
- NCT02090296
- Locations
- 🇺🇸
Children's National Medical Center, Washington, D.C., District of Columbia, United States
Selinexor (KPT-330) in Older Patients With Relapsed AML
- Conditions
- Interventions
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 317
- Registration Number
- NCT02088541
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center / University of California, Los Angeles, Los Angeles, California, United States
🇳🇱VU University Medical Center, Amsterdam, Netherlands
🇺🇸Colorado Blood Cancer Institute/Sarah Cannon Research Institute, Denver, Colorado, United States
Novel Dose Escalation to Predict Treatment With Hydroxyurea
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 70
- Registration Number
- NCT02042222
- Locations
- 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
Novel Use Of Hydroxyurea in an African Region With Malaria
- Conditions
- Interventions
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 208
- Registration Number
- NCT01976416
- Locations
- 🇺🇬
Mulago Hospital Sickle Cell Clinic, Kampala, Uganda
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.